Chris Buyse serves as a member of the board of directors of the Company since 2008. He brings over 25 years of international financial expertise and experience. He is currently Managing Director of Life Sciences Research Partners VZW, a non-profit organization supporting and investing in innovative companies active in life sciences. He is also setting up Fund+NV/SA, a fund that will invest in Belgian biotech companies. Between August 2006 and June 2014, Mr. Buyse served as the Chief Financial Officer (CFO) and board member of ThromboGenics NV, a leading biotech company that is listed on NYSE Euronext Brussels. Before joining ThromboGenics, he was the CFO of the Belgian biotech company CropDesign, where he coordinated the acquisition by BASF in July 2006. Prior to joining CropDesign he was financial manager of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecommunication companies and he was also the CFO and interim CEO of Keyware Technologies. Mr. Buyse holds a master degree in applied economic sciences from the University of Antwerp and an MBA from Vlerick School of Management in Gent. He currently serves, as member of the board of directors of the following publicly and privately held companies: Bone Therapeutics SA, Orgenesis Inc. Iteos SA, Bioxodes SA, Bio Incubator NV, Immo David NV, Pinnacle Investments SA, CreaBuild NV, Sofia BVBA, Pienter-Jan BVBA, Life Sciences Research Partners VZW (a shareholder of the Company) and Keyware Technologies NV.